Login to Your Account

Financings Roundup

Topica Raises $27M Series B For Nail Antifungal Trial

By Tom Wall

Wednesday, October 19, 2011
There's a lot of toenail and fingernail fungus among us, enough that Topica Pharmaceuticals Inc., has raised $27 million in a Series B financing to support a Phase IIb/III trial of the privately held Palo Alto, Calif.-based biotech's luliconazole topical antifungal agent for treatment of onychomycosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription